Article info
Commentary
Pharmacological interventions
Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia
- Correspondence to Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY 10595, USA; citrome{at}cnsconsultant.com
Citation
Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia
Publication history
- Received April 22, 2018
- Revised May 17, 2018
- Accepted May 17, 2018
- First published June 26, 2018.
Online issue publication
July 30, 2018
Article Versions
- Previous version (26 June 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.